Drug Search Results

Linopirdine

Alternative Names: linopirdine, aviva
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TRPV1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Chile | Dominican Republic | Hong Kong | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Linopirdine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date
UMemphis	N/A	Recruiting	Depressive Disorder\|Suicidality	2027-08-01
Riphah international universit	N/A	Recruiting	Unknown	2025-02-01
CairoU 4 7 22	N/A	Recruiting	Mucositis\|Dental Plaque\|Tooth Loss\|Gingivitis\|Glossitis\|Stomatitis\|Dental Caries	2024-12-01
IDT-1608-AL	N/A	Completed	General Diabetes	2017-03-01

Recent News Events

Date	Type	Title
12/19/2024	News Article	Two 2025 Kathy A. Possinger Housing Policy Fellows announced
12/17/2024	News Article	NXP to Acquire Automotive Networking Pioneer Aviva Links, Accelerating Asymmetrical ASA Multi-Gigabit Connectivity in Software Defined Vehicles
12/12/2024	News Article	Industry-leading Data Conference—DataDriven—to Feature AI Futurist and Top Data Leaders from Fortune 500 Companies
11/27/2024	News Article	Slate Asset Management Acquires Morrisons Regional Distribution Center in Bridgwater, United Kingdom
06/05/2024	PubMed	The antidiabetic drug ipragliflozin induces vasorelaxation of rabbit femoral artery by activating a Kv channel, the SERCA pump, and the PKA signaling pathway.
04/08/2024	PubMed	A guide to selecting high-performing antibodies for RNA-binding protein TIA1 for use in Western Blot, immunoprecipitation and immunofluorescence.
11/01/2023	PubMed	LGBTQ-competent obesity prevention and management.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions